
Faculty of Science

Faculty Publications

This is a post-review version of the following article:

A microfluidic toolbox for cell fusion

Flora W.Y. Chiu, Hakan Bagci, Amanda G. Fisher, Andrew J. deMello, Katherine S. Elvira

2016

The final published version of this article can be found at:

<https://doi.org/10.1002/jctb.4803>

Citation for this paper:

Chiu, F.W.Y., Bagci, H., Fisher, A.G., deMello, A.J. & Elvira, K.S. (2016). A microfluidic toolbox for cell fusion. *Journal of Chemical Technology & Biotechnology*, 91(1), 16-24. <https://doi.org/10.1002/jctb.4803>

A microfluidic toolbox for cell fusion

Flora Wing Yin Chiu,¹ Hakan Bagci,² Amanda G. Fisher,² Andrew J. deMello¹ and Katherine S.

Elvira^{1,*}

¹Institute of Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH

Zürich, 8093 Zürich, Switzerland

²Lymphocyte Development Group, MRC Clinical Sciences Centre, Imperial College, Hammersmith

Hospital Campus, Du Cane Road, London W12 0NN, UK

*katherine.elvira@chem.ethz.ch

Abstract

Cellular fusion is a key process in many fields ranging from historical gene mapping studies and monoclonal antibody production, through to cell reprogramming. Traditional methodologies for cell fusion rely on the random pairing of different cell types and generally result in low and variable fusion efficiencies. These approaches become particularly limiting where substantial numbers of bespoke one-to-one fusions are required, for example for in-depth studies of nuclear reprogramming mechanisms. In recent years, microfluidic technologies have proven valuable in creating platforms where the manipulation of single cells is highly efficient, rapid and controllable. These technologies also allow the integration of different experimental steps and characterisation processes into a single platform. Although the application of microfluidic methodologies to cell fusion studies is promising, current technologies that rely on static trapping are limited both in terms of the overall number of fused cells produced and their experimental accessibility. Here we review some of the most exciting breakthroughs in core microfluidic technologies that will allow the creation of integrated platforms for controlled cell fusion at high throughput.

Keywords: droplet microfluidics, cell fusion, cell encapsulation, single-cell, high efficiency, cell sorting.

27 **Introduction**

28 Cellular fusion is an important part of the normal growth and development of organisms, ranging from yeast to
29 humans.¹ The process occurs naturally, and the most prominent example of developmentally induced cell fusion
30 is between an oocyte and a sperm cell, which gives rise to a fertilized egg and hence the generation of a new
31 life.² The importance of cell fusion can also be exemplified by other biological processes such as the
32 development of skeletal muscles (myoblast fusion), bones (osteoclast fusion) and placentae (trophoblast
33 fusion).³⁻⁵ Moreover, cell fusion plays a key role in innate immune responses, as macrophages can fuse to form
34 multinucleated giant cells which can engulf and destroy pathogens.⁶ Cell fusion also takes place in lower
35 eukaryotes such as *Caenorhabditis elegans* (epidermal cell fusion) and *Drosophila melanogaster* (myoblast
36 fusion).^{1,7} On the other hand, failed or unregulated cell fusion is implicated in human diseases.⁸ Despite the
37 importance of these processes in living organisms, very little is known about the mechanism of cell fusion or the
38 factors that control the fusion process.^{9,10} Accordingly, much research has been directed towards the study of
39 cellular membrane fusion and the cellular components and signalling factors involved, with fusion involving
40 human cell types being of particular interest due to its therapeutic significance.¹¹

41 In addition to cell fusion within physiological environments, cell fusion *in vitro* has also been reported. Fusion
42 of cells of the same species or of different species results in the formation of homokaryons or heterokaryons
43 respectively, where the nuclei of the fusion partners are included in a single cytoplasm but remain separate and
44 stable over time (up to a few days, depending on cell type and culture conditions).^{12,13} Growth and division
45 processes can also occur in homo- or heterokaryons, where nuclei are subsequently fused to give proliferating
46 hybrid cells that contain double the genome dose.¹⁴ The possibility to fuse cells of distinct cell types has
47 attracted much interest in molecular biology. For example, heterokaryons, in which nuclei of different cell types
48 are contained in the same cytoplasm, serve as a valuable experimental system to study the control of gene
49 expression and the impact of one genome on another.¹² In addition, fusing cells at different states of
50 differentiation or at different stages of the cell cycle allows the study of genetic complementation and cellular
51 dominance or differentiation plasticity.¹⁵ Indeed, in recent times, cell fusion has become an experimental tool to
52 induce nuclear reprogramming, a process by which the fate of a cell is altered.¹⁴ Nuclear reprogramming falls
53 into two broad categories: pluripotent reprogramming, in which the differentiated state of a cell can be reversed
54 back to a pluripotent embryonic stem-like state, and lineage reprogramming, in which the differentiated state of
55 a cell is directly switched into another.¹⁶ For instance, it has been reported that the reprogramming of human B
56 lymphocytes by mouse ES (mES) cells can be achieved by cell fusion *in vitro*, where the resultant

57 reprogrammed B cells elicit the expression of a human ES-specific gene profile.¹⁷ The development of nuclear
58 reprogramming technology has led to great excitement in the scientific community regarding the potential use of
59 reprogrammed cells to not only improve the understanding and treatment of diseases, but also in patient-specific
60 cell replacement therapies.¹⁸ Nevertheless, there is a need for a better mechanistic understanding of the
61 reprogramming process. In particular, characterisation of the factors and regulators required for efficient
62 derivation of induced pluripotent stem (iPS) and somatic stem cells and how they can subsequently be induced
63 to differentiate towards the cell type of interest is critical.¹⁹ In this respect, heterokaryons act as a useful tool to
64 study nuclear reprogramming, because the effects of trans-acting factors specific for one cell type on altering the
65 transcriptional programme of the partner can be investigated. It also allows examination of the earliest
66 molecular events that occur in the nucleus during reprogramming that have until now been difficult to capture.
67 Furthermore, interspecies heterokaryons have the additional benefit of allowing gene expression changes to be
68 sensitively monitored on the basis of species-specific genetic differences, so that key events in successful
69 reprogramming can be uncovered.^{17,20}

70 Hybrid cells are also important tools for molecular biology. When cultured, the predominant growth of hybrid
71 variants that have lost chromosomes derived from either one or both parental cell types becomes evident. Taking
72 advantage of this, gene mapping²¹ has been historically used to map specific phenotypes to gene products.
73 Hybrids generated between tumour and normal somatic cells have also been widely used for malignancy
74 studies.²² Most importantly, the use of hybrid cells has led to the development of promising therapeutic
75 applications²³, of which the production of hybridomas (hybrid cells between an immortalised cell and an
76 antibody producing lymphocyte), and hence the generation of monoclonal antibodies (mAb) against an antigen
77 of choice, is the most well-known. This technique was first introduced in the 1970s²⁴ and has been implemented
78 extensively over the past few decades as a source of humanised monoclonal antibodies in targeted cancer
79 therapies.²⁵ More recently developed cellular-based cancer vaccinations are another key application derived
80 from hybrid cells. This technology is based on the fusion of dendritic cells and tumour cells, from which the
81 hybrid cells can induce an anti-tumour specific immune response. Such an approach has been shown to be
82 effective both *in vitro* and *in vivo*, and a plethora of clinical trials have been conducted.²⁶

83 Despite its utility in a variety of applications, current methods for achieving cell fusion among cell populations
84 *in vitro* are cumbersome and inefficient. They include the use of inactivated Sendai virus, polyethylene glycol
85 (PEG), focused laser beams and electric pulses, of which PEG-mediated fusion and electrofusion represent the
86 most commonly used techniques due to their relative simplicity.²⁷⁻³¹ Electrofusion is achieved through

87 electroporation³²: as cells are exposed to short pulses of a high-strength DC voltage, membrane reorganisation
88 occurs, resulting in the formation of nanopores. Electroporation is reversible and pores on two cells under
89 investigation must come into contact so that membrane connection can be induced. However, the use of
90 excessive fields can result in cell rupture and lysis. Cell-to-cell connection facilitates cytoplasmic exchange
91 between the two cells and eventually fusion between the pair. The mechanism of PEG-mediated fusion³³ is
92 slightly different. The major effect of PEG is volume exclusion, which enables the formation of large areas of
93 close membrane contact between cells. Subsequent removal of PEG and incubation of cells leads to the
94 formation of small cytoplasmic bridges between cells, with the expansion of these cytoplasmic connections
95 (promoted by cell swelling) resulting in fusion. The major drawback of such bulk cell fusion methods is that
96 they rely on random initial cell-cell pairing, making it extremely difficult to fuse in a selective and controllable
97 manner. Fusion efficiencies when using PEG as fusogen are also generally low. For example, using PEG to
98 chemically fuse mES and human B cells typically yields between 10 and 15% viable heterokaryons.^{17,34}
99 Electrofusion has been shown to give higher efficiencies when compared to PEG treatment³⁵ (varying
100 considerably with cell type) but the other drawbacks mentioned above remain unresolved. This prevents, for
101 example, detailed mechanistic studies of fusion-mediated reprogramming, as screening of substantial numbers
102 of heterokaryons fused in one-to-one ratio, is required. Additionally, for other applications such as hybridoma
103 production and cell vaccine preparation, an efficient protocol is clearly needed. To this end, a more robust
104 methodology that allows cell-to-cell fusion in high throughput and in a controlled manner is required.


105

106 **Current microfluidic platforms for cell fusion**

107 Microfluidic systems precisely control fluids that are geometrically constrained in sub-millimetre scale
108 environments, and offer many advantages for cell manipulation such as the ability to use small quantities of
109 samples and reagents, reduced analysis times and the possibility to conduct studies at the single cell level.
110 Examples of reported applications include on-chip long-term cell culture³⁶, cell trapping³⁷, cell screening^{38,39} and
111 cell patterning.⁴⁰ Microfluidic systems for cell fusion have also been developed. In particular, much research has
112 focused on the use of electrofusion to accomplish cell fusion due to the ease of microelectrode integration within
113 a planar chip format and the ability to precisely manipulate electric fields, in both space and time, at a scale
114 comparable to that of a biological cell. A recent review by Hu *et al.*⁴¹ provides a detailed account of this class of
115 microfluidic systems and therefore only key literature will be highlighted in here. In brief, most of these systems
116 incorporate continuous fluid flows and consist of a microfluidic channel along which an array of

117 microelectrodes is fabricated. These microelectrodes are designed such that the electric field is non-uniform
 118 within the channel, with higher field strengths at specific positions. For example, Hu *et al.*⁴² used an array of
 119 protruding microelectrodes such that when an AC electric field is applied, cells flowing along a microfluidic
 120 channel are attracted to the side-wall surfaces of the protruding electrodes due to the higher field strength. This
 121 was then followed by cell alignment due to dielectrophoresis (**Figure 1a**). Cells can then be exposed to high
 122 direct current (DC) pulses, to induce (reversible) electroporation and ultimately cell fusion.⁴² Generally
 123 speaking, the interplay between microelectrode geometry and electric field governs pairing efficiencies in this
 124 type of devices, which typically fall in the range of 40 to 70%.⁴¹ The major disadvantage of using protruding
 125 microelectrode arrays is that cells can be trapped in areas between adjacent electrodes (indicated by white
 126 circles in **Figure 1a**). In these areas, electric field strength is lower, resulting in reduced fusion efficiencies.
 127 Moreover, pairing of cells is still a random process, where both homogenous and heterogeneous cell pairing can
 128 occur. Similar to bulk electrofusion methodologies, multi-cell fusion can occur in this type of microfluidic
 129 platforms and separation of fused cells from non-fused cells on-chip is not possible.

130



131

132 **Figure 1.** Microfluidic platforms for cell fusion. a) Cell alignment in flow in a microchannel with an integrated
 133 microelectrode array such that electric field strength at sidewall surfaces of the protruding electrodes is higher
 134 than other positions of the channel. The red dotted circles show cell pairs aligning at the surfaces of protruding

135 electrodes and white circles show cells trapped in between adjacent protruding electrodes.⁴² Reprinted with
136 permission from *Biomicrofluidics* 5, 034121 (2011). Copyright 2011, AIP Publishing LLC. b) Fluorescent
137 image of fused cells created via the flow-through method proposed by Wang *et al.*⁴³ Cells are pre-conjugated
138 based on biotin-streptavidin interactions and the red circles highlight fused cells where one cell is labelled with
139 calcein AM and is one unlabelled. Reprinted with permission from *Appl. Phys. Lett.* 89, 234102 (2006).
140 Copyright 2006, AIP Publishing LLC. c) Three-step loading protocol to pair different cell types in weir-based
141 cell traps (the scale bar is 50 μm) and d) overlay of red and green fluorescence images of cells after loading
142 and pairing using traps shown in (c) (the scale bar is 200 μm).⁴⁴ Reprinted by permission from Macmillan
143 Publishers Ltd: *Nature Methods* 6, 147 - 152 (2009), copyright 2009.

144


145 To truly improve the efficiency of cell fusion, both the mechanism of initiation of membrane fusion as well as
146 control over how cells are brought into contact with each other and paired, are critical. At the same time,
147 undesirable fusion events, such as those between the same cell type or multi-cell fusion, must be avoided or
148 removed from final samples. Cell pairing by chemical methods or microstructures have been proposed to
149 improve fusion yield. For example, Wang *et al.* reported a flow-through method in which cells are introduced
150 into a narrow microfluidic channel (designed to contain no more than three cells across the channel), followed
151 by the application of a continuous, DC voltage to initiate fusion, using electrodes integrated on-chip (**Figure**
152 **1b**).⁴³ Using this system, fusion of Chinese hamster ovary cells was demonstrated. Cells were conjugated based
153 on biotin-streptavidin interaction before being subjected to an electric field. Depending on the electric field
154 strength, the number of pulses applied and their duration, about 40% of the total number of cells loaded in
155 device were fused and remained viable. Despite showing an improved efficiency when compared to
156 conventional bulk methods, this approach lacks the ability to controllably pair cells, and thus the overall fusion
157 yield is still low. Skelley *et al.* proposed the use of weir-based cell traps arrayed within a microfluidic channel
158 (**Figure 1c and 1d**).⁴⁴ A key advantage of this method is that cell pairing relies solely on passive
159 hydrodynamics, thus obviating the need for label-modified cells. Additionally, cell pairs are held close in
160 contact in the traps, which is a prerequisite for successful cell fusion. Both electrofusion and PEG-mediated
161 fusion can be accommodated in this system using mES cells, mouse embryonic fibroblasts (mEFs), myeloma
162 cells, B cells and NIH3T3 fibroblasts to give rise to hybrid cells. Cell pairing efficiencies of up to 70% were
163 demonstrated with overall fusion efficiencies significantly higher than conventional bulk protocols or
164 commercial fusion chambers. However, the percentage of fused cells recovered from the device post-fusion and

165 their viability were not reported. Reprogramming of mEFs *via* fusion with mES cells⁴⁴ and pair-wise interaction
166 studies of mouse lymphocytes at a single-cell level⁴⁵ have also been performed using this system. Using a very
167 similar cell-trapping microdevice, but implementing a deformability-based approach (use of high flow rates
168 caused cells to deform and were hence squeezed through a constriction into each cell trap) to capture and pair
169 cells, Dura *et al.* reported pairing and electrofusion efficiencies of up to 80% and 95% respectively, and an
170 overall yield (fusion between correctly paired cells) of 56%.⁴⁶ This system also has the potential to fuse more
171 than two cell partners. However, the exposure of cells to hypoosmolar buffer would be necessary to facilitate
172 fusion of cells with a large difference in cell size, and since different cell types vary in their responses to
173 deformation, excessive hydrodynamic forces induced within the device could impair cell viability. Overall, the
174 application of these trap systems although promising, is limited as only a few thousand traps can be included in
175 a single device.

176 Another interesting approach to perform cell fusion on-chip involves the use of micro-orifices to create an
177 electric field constriction. The idea of field constriction using a micro-orifice for cell fusion was first proposed
178 by Masuda *et al.*⁴⁷ in 1989 and later adopted by Techaumnat *et al.*⁴⁸ to perform real-time observation of cell
179 fusion. In this system, two parallel microfluidic channels are separated by an insulating barrier along which an
180 orifice is created (**Figure 2a**). When an AC voltage is applied across the electrodes, the presence of the
181 insulating barrier results in a concentration of electric field lines at the small orifice. Cells are therefore attracted
182 to, and forced into contact with each other, at the orifice based on dielectrophoresis. Electroporation and
183 subsequent cell fusion were then induced by further application of a pulsed voltage. Most importantly, under the
184 applied electric field, only one-to-one cell fusion between the cell pair in the orifice was plausible, even when
185 cell chains are formed near the orifice. To further improve fusion yield, Gel *et al.*⁴⁹ developed a device
186 comprised of an array of micro-orifices (**Figure 2b**). By modifying the mould fabrication process, the orifice
187 size could be tailored (ranging from 2-10 μm) to accommodate different cell types and sizes.⁵⁰ For instance,
188 fusion of mouse fibroblasts using the device shown in **Figure 2b** resulted in a pairing efficiency of 95-100% and
189 a fusion efficiency of over 95%. Nevertheless, the throughput of this type of devices is generally low due to the
190 limited number of orifices that can be created along the channel. At the upper limit, Kimura *et al.*⁵¹ fabricated a
191 micro-orifice array sheet that could accommodate up to 6×10^3 micro-orifices in a two-dimensional arrangement
192 (**Figure 2c and 2d**). Using this device, fusion yield was reported to be about 80%. Despite the high fusion yield,
193 the throughput of this method is still relatively low. Furthermore, operation of the device is rather complex, as
194 pairing of cells relies on not only the dielectrophoretic force, but also on cell sedimentation. In other words, the

195 device had to be flipped over whilst keeping the voltage on (to keep cells in the upper chamber trapped at the
 196 orifices), in order to allow cells from the lower chamber to sediment and reach orifices for pairing and fusion
 197 (Figure 2e).

198



199

200 **Figure 2.** a) Cell pairing based on field constriction at a micro-orifice.^{41,47} Reproduced from *Sens. Actuators B*
 201 *Chem.* **178**, 63 (2013) with permission of Elsevier. b) Schematic of a microfluidic device containing an array of
 202 micro-orifices for cell fusion as proposed by Gel et al.⁴⁹ Reproduced from *Biomicrofluidics* **4**, 022808 (2010)
 203 with permission of AIP Publishing LLC. c) Structure of a micro-orifice array sheet and d) SEM images of the
 204 corresponding micro-orifices.⁵¹ e) Schematic of the cell pairing process on the orifice sheet: (i) under applied
 205 electric field, cells in the top chamber (green circles) are attracted to orifices due to dielectrophoresis, (ii) the
 206 device is then flipped over whilst keeping the voltage on to allow (iii) cell pairing when cells originally in the
 207 lower chamber (red circles) fall into orifices via both sedimentation and dielectrophoresis.⁵¹ Reproduced from
 208 *Electrophoresis* **32**, 2496 (2011) with permission of Wiley.

209

210 **Droplet-based microfluidic platforms for cell fusion**


211 Droplet-based microfluidic technologies could offer the highest potential and versatility for single-cell studies.
212 These platforms usually involve the generation of monodisperse aqueous droplets in a continuous oil phase,
213 where each droplet effectively acts as an individual and isolated reaction chamber.⁵² Droplets can be generated
214 and manipulated at kHz rates, with each droplet having volumes between a few femtoliters and hundreds of
215 nanoliters. Droplet contents can be varied, exchanged or sampled using a large variety of merging, splitting and
216 sorting strategies,^{53–57} and droplets significantly can support living cells and organisms for many days through
217 the use of highly gas-permeable fluorinated oil phases and biocompatible surfactants.⁵⁶ Another key advantage
218 of droplet microfluidic systems is the ease of integration of multiple experimental and analytical steps within a
219 single platform. This makes them particularly suitable for single-cell studies, which usually involve complex
220 workflows. For example, Cho *et al.*⁵⁸ describe the first fully integrated and high-throughput droplet-based
221 microfluidic platform for the assessment of photodynamic therapy photosensitizer efficacy. This system enabled
222 screening almost an order of magnitude faster than conventional methods. Perhaps the most interesting feature
223 of the approach is its ability to gather multidimensional information in a rapid fashion; in this case the authors
224 were able to measure the effect of oxygen saturation and dark toxicity in the same device, an operation not
225 possible using traditional methods.

226 Not surprisingly, performing cell fusion in droplets has been attempted. Schoeman *et al.* reported a platform that
227 allows parallel encapsulation of HL60 cells in two separate streams, pairing and merging of the droplets formed,
228 and droplet shrinkage of merged droplets to promote cell contact for subsequent electrofusion. They achieved
229 pairing and merging of droplets with efficiencies close to 100% and 95% respectively, and ultimately 40% of
230 merged droplets were shown to contain exactly two HL60 cells. This platform was, however, only tested with
231 one cell type, and, surprisingly, the authors did not perform the final step of cell fusion within the device.⁵⁹
232 Nevertheless, it is clear that the use of droplets potentially affords the high degree of control required for
233 efficient cell fusion in a high-throughput manner. Furthermore, there are other microfluidic techniques that can
234 be leveraged to overcome the current limitations of this platform. In the final section of this review we describe
235 droplet-based microfluidic tools or building blocks that can be used to create an integrated platform for cell
236 fusion studies with the aim of encouraging research in this field.

237 The first component required to enable the realisation of a fully integrated droplet-based⁶⁰ microfluidic platform
238 for cell fusion is the encapsulation of cells within droplets. More specifically, the correct number of cells must
239 be brought together in each droplet, which in most cases means one of each cell type. This can be achieved

240 using two different approaches. The first involves single-cell encapsulation of each fusion partner separately,
 241 followed by droplet merging to bring the desired cells together inside the united droplet.⁵⁹ The second approach
 242 involves the co-encapsulation of the two cell types during droplet formation such that one cell of each type is
 243 delivered to each droplet.⁶¹

244



245

246 **Figure 3.** Droplet-based microfluidic tools for cell fusion. a) and b) Dean-coupled inertial ordering in curved
 247 channels to allow high-efficiency single cell encapsulation in droplets.⁶² Reproduced from *Lab Chip*, **12**, 2881
 248 (2012) with permission of The Royal Society of Chemistry. c) Droplet sorting via dielectrophoresis. Main image
 249 shows sorting of droplets when an AC electric field is applied (droplets were deflected towards the upper
 250 channel). Inset image shows droplets flowing into the lower channel (due to hydraulic resistance in the absence
 251 of applied electric field).⁵⁶ Reproduced from *Lab Chip*, **9**, 1850 (2009) with permission of The Royal Society of
 252 Chemistry. d) Synchronisation of two populations of pre-formed droplets followed by electrocoalescence of the

253 *synchronised droplet pairs*.⁶³ Reproduced from *Lab Chip*, **14**, 509 (2014) with permission of The Royal Society
254 of Chemistry.

255

256 Traditional methods for single cell encapsulation use diluted cell samples and deliver cells to a droplet
257 generation nozzle in a random fashion. This yields a population of droplets with a Poissonian-distributed cell
258 occupancy⁶⁴, i.e.

$$259 \quad P_{\lambda,k} = \lambda^k \exp(-\lambda)/k!$$

260 Here $P_{\lambda,k}$ is the probability of a droplet containing k number of cells, with λ being the mean number of cells *per*
261 droplet. Single cell encapsulation efficiencies in this case are generally low, for example, the probability of a
262 droplet containing only one cell is limited to 36.8% when $\lambda = 1$.⁶¹ However, to avoid droplets containing
263 multiple cells, diluted samples are normally used. For instance, for $\lambda = 0.3$, the probability of droplets
264 containing a single cell is around 22%, and while 74% of the droplets formed will be empty, only around 3.7%
265 will contain two cells or more.⁶⁵ Co-encapsulation of cell pairs of two distinct cell types based on Poissonian
266 statistics will occur with even lower efficiencies, with the probability of a droplet containing one cell of each
267 type being limited to 13.5%.⁶¹ However, the use of this method to encapsulate both fusion partners
268 simultaneously into the same droplet does not require droplet paring and merging, and the handling of cells prior
269 to fusion can hence be minimised. In light of the limits imposed by Poissonian statistics, various methods have
270 been developed to increase encapsulation efficiencies beyond the predicted probabilities (for both the case of
271 single cell encapsulation and co-encapsulation). In this respect, inertial microfluidic strategies have gained much
272 popularity in recent years.⁶⁶ These passive methods make use of the inertial lift forces within narrow and high
273 aspect ratio channels to focus (at specific cross-sectional positions in a microchannel) and/or order (regular cell-
274 to-cell distances) cells prior to encapsulation.⁶⁷ Subsequently, by matching the periodicity of cell flow with
275 droplet generation, cell encapsulation efficiencies can be significantly increased. Edd *et al.*⁶⁸ first demonstrated
276 self-ordering of HL60 cells *via* inertial migration within a straight rectangular microchannel of just 6 cm in
277 length. The system was tested using samples with a range of cell densities and resulted in much higher fractions
278 of droplets with single-cell occupancy when compared to experiments without ordering. For example, with a
279 cell sample of $\lambda = 0.5$, over 50% of droplets were shown to have only one cell, while droplets with multiple
280 cells were kept below 5%. Employing the same ordering channel, Lagus *et al.*⁶¹ generated ordered trains of two
281 separate strains of *C. reinhardtii* cells and performed co-encapsulation. The reported co-encapsulation efficiency

282 of one cell of each strain in a droplet showed a two-fold improvement compared to that based on Poissonian
283 statistics. Kemna *et al.*⁶² achieved ordering of HL60 and K562 cells within a curved channel with a single cell
284 encapsulation efficiency of almost 80% (**Figure 3a and 3b**). Due to the use of curved channels, additional Dean
285 forces are introduced, and in combination with the inertial forces, cells are focused and ordered efficiently.⁶⁹

286 The platform proposed by Schoeman *et al.*⁵⁹ described previously also made use of Dean-coupled inertial
287 ordering to enhance single-cell encapsulation efficiency. In this case, the efficiency of single cell encapsulation
288 was close to 70%. That said, the primary drawback of inertial microfluidic strategies is the requirement for
289 relatively high flow rates, which may compromise the survival rates of cells post-encapsulation. Also, for cell
290 populations that have large intrinsic size variations, inter-cell ordering distances may vary considerably, making
291 controlled single cell encapsulation challenging. Chabert *et al.*⁷⁰ reported another approach based purely on
292 passive hydrodynamics to increase single cell encapsulation efficiencies. This system utilised cell-triggered
293 Rayleigh-Plateau instabilities induced in a jet flow⁷¹ to encapsulate cells and create monodisperse droplets.
294 Resulting droplets underwent self-sorting on the basis of two hydrodynamic mechanisms: lateral shear-induced
295 drift⁷² and sterically driven dispersion, with up to 80% of the sorted droplets containing only one cell and with
296 less than 1% of droplets being empty.

297 An alternative strategy to such passive methods is to actively sort droplets containing cells from empty droplets.
298 Baret *et al.* developed the first system capable of sorting picoliter-sized droplets according to their fluorescent
299 signature based on dielectrophoresis (**Figure 3c**).⁵⁶ To validate the system, mixtures of two different strains of
300 *E. coli* cells (expressing either the reporter enzyme β -galactosidase or an inactive variant) were first emulsified
301 with a fluorogenic substrate, followed by re-injection of the pre-formed droplets into the sorting system to
302 separate the population of droplets containing the active variant, which were 100-fold more fluorescent upon
303 hydrolysis with the fluorogenic substrate than the inactive variant. The sorting throughput was 300 droplets *per*
304 second, with a false positive error rate of less than 1 out of 10^4 droplets. Mazutis *et al.*⁶⁵ integrated a similar
305 sorting system into their droplet-based platform for binding assays. Depending on various factors including the
306 flow rates of emulsion and fluorinated oil (for spacing droplets) flows and the duration of the sorting pulse, this
307 type of sorter system can sort droplets at rates up to 2 kHz.^{56,65,73} However, this is still much lower than
308 commercially available fluorescence-activated cell sorters (FACS), which can sort at rates of up to 50 kHz⁷⁴
309 (although FACS sorts based on a continuous flow and cells are not compartmentalised individually like in the
310 case of droplets). Recently, Sciambi *et al.*⁵⁷ described a sorter that can accurately sort 25 μm -sized droplets
311 encapsulated with fluorescent beads at rates up to 30 kHz. This system was designed based on the

312 aforementioned system, but with new microstructures called gap dividers being introduced to the device to
313 reduce droplet splitting at the sorting junction as well as to minimise oil spacer flow rate, which are the major
314 factors limiting throughput in previously reported sorters. This system is ten times faster than existing droplet-
315 sorters and provides better enrichment of specific droplet subpopulations. Moreover, since the use of this type of
316 sorting systems is independent of the cell type involved or cell size, they are more robust and reliable than
317 passive methods for obtaining droplets encapsulating a targeted number of cells.

318 Once populations of single cells in droplets are achieved in the required numbers, there are two important and
319 closely related microfluidic processes required for realising cell fusion, namely droplet synchronisation (pairing)
320 and droplet merging (fusion). In other words, droplets containing cell fusion partners have to be brought into
321 contact with each other and fused to create one entity. The most straightforward methods are passive and simply
322 involve ensuring that the two populations of droplets flow in a sequential manner that causes pairing. Droplet
323 fusion can then be realised when the synchronised flow is subjected to a merging architecture downstream. A
324 range of strategies for producing paired droplet streams have been reported. For example, the use of combined
325 T-junctions,^{59,75,76} where synchronisation is achieved on the basis of hydrodynamic coupling and pressure
326 equilibration between the two droplet flows has proved popular. A similar system integrated with a passive
327 pressure oscillator was proposed by Hong *et al.*,⁷⁷ and Schoeman *et al.*⁵⁹ used a double T-junction to achieve
328 synchronised formation of droplets containing HL60 cells from two separate streams. Step emulsification (the
329 production of droplets occurs due to a step change in the height of the microchannel at the interface between two
330 immiscible fluids) has also been used to achieve synchronisation.^{78,79} Application of these systems for cell
331 fusion is, however, limited unless it can be coupled with a droplet formation unit that allows high efficiency
332 single cell encapsulation (for example cell ordering prior to encapsulation) or with a droplet sorter, since
333 otherwise the subsequent droplet merging step will cause even lower cell pairing efficiencies. Another strategy
334 is to decouple droplet formation from droplet synchronisation, and use a microfluidic platform that has the
335 ability to synchronise two streams of pre-formed droplets. This provides much more flexibility and control of
336 droplet populations. Lee *et al.*⁶³ demonstrated the synchronization of two different populations of pre-formed
337 droplets *via* the use of opposing T-junctions, with merging of the synchronised droplets also shown in the same
338 device (**Figure 3d**). The synchronisation error rate was 13% with the droplet merging yield approaching 85%.
339 However, Dressler *et al.*⁸⁰ recently reported a different methodology to perform synchronisation also using pre-
340 formed droplets, with error rates less than 0.2%. The only disadvantage of this system is that a large number of
341 droplets are discarded during the synchronisation process, although future refinements could recycle discarded

342 droplets to ensure complete and waste-free synchronisation of the two droplet populations. However, to date,
343 most of these synchronisation methods have not been tested with cell-containing droplets.

344 After a train of single cell-containing droplets has been synchronised in the required sequence, droplet merging,
345 or fusion, must be induced to bring the cells into contact. In most cases, water-in-oil emulsions are stabilised
346 with the use of a surfactant and simply inducing a collision between droplets will not result in merging. To
347 ensure merging, two droplets must be brought into close contact and the surfactant layer covering the droplets
348 must be destabilised. There are multiple methods to induce destabilisation, such as electrical impulses (*i.e.*
349 electrocoalescence),^{63,81,82} addition of a poor solvent for the surfactant,⁸³ laser heating,⁸⁴ or through the use of
350 different concentrations of surfactant.⁸⁵ Perhaps the most challenging part of droplet merging is to bring the
351 droplets into close enough contact for a sufficient period time. This is usually achieved using microstructures
352 on-chip to slow down the leading droplet and allow the following droplet to catch up within the synchronised
353 stream. Examples of reported geometries for this purpose include widening channels,⁸⁶ pillar structures^{63,87} and
354 zig-zag structures.⁸⁵ A more vigorous method to bring droplet together involves the use of on-chip electrodes to
355 attract and deform the lead droplet within the microchannel and allow the continuous phase to flow around the
356 trapped droplet. As the second droplet approaches, merging occurs and the resultant merged droplet is directed
357 along the channel due to pressure upstream.⁸¹ The use of microfluidic tools such as these should enable
358 populations of single cells to be paired in the required order and merged so that they are contained in a single
359 droplet, prior to fusion of the paired cells. To date, no induced fusion of cells within droplets has been reported
360 in the literature, although of the methods for cell fusion described previously, both PEG-mediated and
361 electrofusion of cells have been shown in microfluidic (non-droplet) formats.

362 The integration of cell fusion in droplet-based microfluidic systems will lead to the generation of large numbers
363 of individual heterokaryons that are necessary for more detailed analysis, for example in the case of pluripotent
364 reprogramming. These platforms could be used to assess reprogramming success and failure over time and to
365 examine how transcription factor binding to somatic DNA initiates reprogramming (using for example
366 chromatin immunoprecipitation methods). To enable these studies, reporters of successful reprogramming will
367 need to be engineered within somatic cells (for example fibroblasts carrying Oct4 promoter driven GFP) to
368 allow real-time tracking of events in heterokaryons. In addition, high-throughput cell fusion platforms will allow
369 the application of drug and RNAi-based screens for determining factors that enhance or prevent cellular
370 reprogramming. Overall, it is clear that the components of a droplet-based microfluidic platform for high-
371 efficiency cell fusion are ready and waiting for integration and application to fundamental biological questions.

372 **Conclusions**

373 We hope that this review highlights various wide-ranging microfluidic tools that are available for use in cell
374 fusion studies. The process of single cell encapsulation in droplets, sample enrichment and droplet
375 synchronisation and merging are highly applicable to cell fusion studies and the use of microfluidic technologies
376 to perform and study cell fusion is an emerging and exciting area of research. The inherent ability of such
377 systems to exert high levels of control over single cells whilst enabling the manipulation of thousands of cells
378 *per second* is likely to impact cell fusion studies in a major way, allowing the pairing and fusion of distinct cell
379 types in a controllable, on-demand and high throughput fashion. Such technologies will undeniably prove useful
380 for in-depth biological studies of a variety of cell-based systems.

381

382 **References**

- 383 1. Ogle BM, Cascalho M, and Platt JL. Biological implications of cell fusion. *Nat Rev Mol Cell Biol.* **6**:567–
384 75 (2005).
- 385 2. Wassarman PM, Jovine L, Qi H, Williams Z, Darie C, and Litscher ES. Recent aspects of mammalian
386 fertilization research. *Mol Cell Endocrinol.* **234**:95–103 (2005).
- 387 3. Horsley V, and Pavlath GK. Forming a Multinucleated Cell: Molecules That Regulate Myoblast Fusion.
388 *Cells Tissues Organs.* **176**:67–78 (2004).
- 389 4. Pötgens AJG, Schmitz U, Bose P, Versmold A, Kaufmann P, and Frank H-G. Mechanisms of Syncytial
390 Fusion: A Review. *Placenta.* **23, Supplement A**:S107–13 (2002).
- 391 5. Vaananen HK, Zhao H, Mulari M, and Halleen JM. The cell biology of osteoclast function. *J Cell Sci.*
392 **113**:377–81 (2000).
- 393 6. Vignery A. Osteoclasts and giant cells: macrophage–macrophage fusion mechanism. *Int J Exp Pathol.*
394 **81**:291–304 (2000).
- 395 7. Mohler WA, Shemer G, del Campo JJ, Valansi C, Opoku-Serebuoh E, Scranton V, Assaf N, White JG,
396 and Podbilewicz B. The Type I Membrane Protein EFF-1 Is Essential for Developmental Cell Fusion.
397 *Dev Cell.* **2**:355–62 (2002).
- 398 8. Dittmar T, and Zänker KS, editors. Cell Fusion in Health and Disease. Dordrecht: Springer Netherlands;
399 (2011).
- 400 9. Chen EH, and Olson EN. Unveiling the Mechanisms of Cell-Cell Fusion. *Science.* **308**:369–73 (2005).
- 401 10. Sapir A, Avinoam O, Podbilewicz B, and Chernomordik LV. Viral and Developmental Cell Fusion
402 Mechanisms: Conservation and Divergence. *Dev Cell.* **14**:11–21 (2008).
- 403 11. Shinn-Thomas JH, and Mohler WA. Chapter five - New Insights into the Mechanisms and Roles of Cell–
404 Cell Fusion. In: Jeon KW, editor. International Review of Cell and Molecular Biology. Academic Press;
405 p. 149–209 (2011).
- 406 12. Kennett RH. Cell fusion. *Methods Enzymol.* **58**:345–59 (1979).

- 407 13. Piccolo FM, Pereira CF, Cantone I, Brown K, Tsubouchi T, Soza-Ried J, Merkschlager M, and Fisher
408 AG. Using heterokaryons to understand pluripotency and reprogramming. *Philos Trans R Soc B Biol Sci.*
409 **366**:2260–5 (2011).
- 410 14. Yamanaka S, and Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. *Nature.*
411 **465**:704–12 (2010).
- 412 15. Davidson RL. Control of the differentiated state in somatic cell hybrids. *Symp Soc Dev Biol Soc Dev Biol*
413 *Symp.* **31**:295–328 (1973).
- 414 16. Sanges D, Lluís F, and Cosma MP. Cell-Fusion-Mediated Reprogramming: Pluripotency or
415 Transdifferentiation? Implications for Regenerative Medicine. In: Dittmar DT, Zänker DKS, editors. *Cell*
416 *Fusion in Health and Disease.* Springer Netherlands; p. 137–59 (2011).
- 417 17. Pereira CF, Terranova R, Ryan NK, Santos J, Morris KJ, Cui W, Merkschlager M, and Fisher AG.
418 Heterokaryon-Based Reprogramming of Human B Lymphocytes for Pluripotency Requires Oct4 but Not
419 Sox2. Roopenian DC, editor. *PLoS Genet.* **4**:e1000170 (2008).
- 420 18. Sullivan S, and Eggan K. The potential of cell fusion for human therapy. *Stem Cell Rev.* **2**:341–9 (2006).
- 421 19. Soza-Ried J, and Fisher AG. Reprogramming somatic cells towards pluripotency by cellular fusion. *Curr*
422 *Opin Genet Dev.* **22**:459–65 (2012).
- 423 20. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, and Blau HM. Reprogramming towards
424 pluripotency requires AID-dependent DNA demethylation. *Nature.* **463**:1042–7 (2010).
- 425 21. Kelsell DP, and Spurr NK. Gene mapping using somatic cell hybrids. *Gene Isolation and Mapping*
426 *Protocols.* Springer; p. 45–52 (1997).
- 427 22. Miller FR, Mohamed AN, and McEachern D. Production of a More Aggressive Tumor Cell Variant by
428 Spontaneous Fusion of Two Mouse Tumor Subpopulations. *Cancer Res.* **49**:4316–21 (1989).
- 429 23. Kandušer M, and Ušaj M. Cell electrofusion: past and future perspectives for antibody production and
430 cancer cell vaccines. *Expert Opin Drug Deliv.* **11**:1885–98 (2014).
- 431 24. Köhler G, and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity.
432 *Nature.* **256**:495–7 (1975).
- 433 25. Scott AM, Wolchok JD, and Old LJ. Antibody therapy of cancer. *Nat Rev Cancer.* **12**:278–87 (2012).
- 434 26. Strioga MM, Felzmann T, Powell Jr. DJ, Ostapenko V, Dobrovolskiene NT, Matuskova M, Michalek J,
435 and Schijns VEJC. Therapeutic Dendritic Cell-Based Cancer Vaccines: The State of the Art. *Crit Rev*
436 *Immunol.* **33**:489–547 (2013).
- 437 27. Harris H, Miller OJ, Klein G, Worst P, and Tachibana T. Suppression of Malignancy by Cell Fusion.
438 *Nature.* **223**:363–8 (1969).
- 439 28. Pontecorvo G. Production of mammalian somatic cell hybrids by means of polyethylene glycol treatment.
440 *Somatic Cell Genet.* **1**:397–400 (1975).
- 441 29. Miller RA, and Ruddle FH. Pluripotent teratocarcinoma-thymus somatic cell hybrids. *Cell.* **9**:45–55
442 (1976).
- 443 30. Teissie J, Knutson VP, Tsong TY, and Lane MD. Electric Pulse-Induced Fusion of 3T3 Cells in
444 Monolayer Culture. *Science.* **216**:537–8 (1982).
- 445 31. Long MA, and Rossi FMV. Targeted Cell Fusion Facilitates Stable Heterokaryon Generation In Vitro and
446 In Vivo. *PLoS ONE.* **6**:e26381 (2011).

- 447 32. Zimmermann U. Electric field-mediated fusion and related electrical phenomena. *Biochim Biophys Acta*
448 *BBA - Rev Biomembr.* **694**:227–77 (1982).
- 449 33. Knutton S. Studies of membrane fusion. III. Fusion of erythrocytes with polyethylene glycol. *J Cell Sci.*
450 **36**:61–72 (1979).
- 451 34. Pereira CF, and Fisher AG. Heterokaryon-Based Reprogramming for Pluripotency. In: Bhatia M, Elefanty
452 AG, Fisher SJ, Patient R, Schlaeger T, Snyder EY, editors. *Current Protocols in Stem Cell Biology*.
453 Hoboken, NJ, USA: John Wiley & Sons, Inc.; (2009).
- 454 35. Hui SW, and Stenger DA. [16] Electrofusion of cells: Hybridoma production by electrofusion and
455 polyethylene glycol. In: Nejat Duzgunees, editor. *Methods in Enzymology* [Internet]. Academic Press; p.
456 212–27 (1993).
- 457 36. Halldorsson S, Lucumi E, Gómez-Sjöberg R, and Fleming RMT. Advantages and challenges of
458 microfluidic cell culture in polydimethylsiloxane devices. *Biosens Bioelectron.* **63**:218–31 (2015).
- 459 37. Yun H, Kim K, and Lee WG. Cell manipulation in microfluidics. *Biofabrication.* **5**:022001 (2013).
- 460 38. Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M, Hutchison JB, Rothberg JM, Link DR,
461 Perrimon N, and Samuels ML. Droplet microfluidic technology for single-cell high-throughput screening.
462 *Proc Natl Acad Sci U S A.* **106**:14195–200 (2009).
- 463 39. Clausell-Tormos J, Lieber D, Baret J-C, El-Harrak A, Miller OJ, Frenz L, Blouwolf J, Humphry KJ,
464 Köster S, and Duan H. Droplet-Based Microfluidic Platforms for the Encapsulation and Screening of
465 Mammalian Cells and Multicellular Organisms. *Chem Biol.* **15**:427–37 (2008).
- 466 40. Mu X, Zheng W, Sun J, Zhang W, and Jiang X. Microfluidics for manipulating cells. *Small.* **9**:9–21
467 (2013).
- 468 41. Hu N, Yang J, Joo SW, Banerjee AN, and Qian S. Cell electrofusion in microfluidic devices: A review.
469 *Sens Actuators B Chem.* **178**:63–85 (2013).
- 470 42. Hu N, Yang J, Qian S, Joo SW, and Zheng X. A cell electrofusion microfluidic device integrated with 3D
471 thin-film microelectrode arrays. *Biomicrofluidics.* **5**:034121–034121 – 12 (2011).
- 472 43. Wang J, and Lu C. Microfluidic cell fusion under continuous direct current voltage. *Appl Phys Lett.*
473 **89**:234102 (2006).
- 474 44. Skelley AM, Kirak O, Suh H, Jaenisch R, and Voldman J. Microfluidic control of cell pairing and fusion.
475 *Nat Methods.* **6**:147–52 (2009).
- 476 45. Dura B, Dougan SK, Barisa M, Hoehl MM, Lo CT, Ploegh HL, and Voldman J. Profiling lymphocyte
477 interactions at the single-cell level by microfluidic cell pairing. *Nat Commun.* **6**: (2015).
- 478 46. Dura B, Liu Y, and Voldman J. Deformability-based microfluidic cell pairing and fusion. *Lab Chip.*
479 **14**:2783 (2014).
- 480 47. Masuda S, Washizu M, and Nanba T. Novel method of cell fusion in field constriction area in fluid
481 integration circuit. *IEEE Trans Ind Appl.* **25**:732–7 (1989).
- 482 48. Techaumnat B, Tsuda K, Kurosawa O, Murat G, Oana H, and Washizu M. High-yield electrofusion of
483 biological cells based on field tailoring by microfabricated structures. *IET Nanobiotechnol.* **2**:93 (2008).
- 484 49. Gel M, Kimura Y, Kurosawa O, Oana H, Kotera H, and Washizu M. Dielectrophoretic cell trapping and
485 parallel one-to-one fusion based on field constriction created by a micro-orifice array. *Biomicrofluidics.*
486 **4**:022808 (2010).

- 487 50. Gel M, Suzuki S, Kimura Y, Kurosawa O, Techaumnat B, Oana H, and Washizu M. Microorifice-Based
488 High-Yield Cell Fusion on Microfluidic Chip: Electrofusion of Selected Pairs and Fusant Viability. *IEEE*
489 *Trans NanoBioscience*. **8**:300–5 (2009).
- 490 51. Kimura Y, Gel M, Techaumnat B, Oana H, Kotera H, and Washizu M. Dielectrophoresis-assisted
491 massively parallel cell pairing and fusion based on field constriction created by a micro-orifice array
492 sheet. *ELECTROPHORESIS*. **32**:2496–501 (2011).
- 493 52. Joensson HN, and Andersson Svahn H. Droplet Microfluidics-A Tool for Single-Cell Analysis. *Angew*
494 *Chem Int Ed*. **51**:12176–92 (2012).
- 495 53. Niu X, Gulati S, Edel JB, and deMello AJ. Pillar-induced droplet merging in microfluidic circuits. *Lab*
496 *Chip*. **8**:1837–41 (2008).
- 497 54. Link DR, Anna SL, Weitz DA, and Stone HA. Geometrically Mediated Breakup of Drops in Microfluidic
498 Devices. *Phys Rev Lett*. **92**:054503 (2004).
- 499 55. Abate AR, Hung T, Mary P, Agresti JJ, and Weitz DA. High-throughput injection with microfluidics
500 using picoinjectors. *Proc Natl Acad Sci U S A*. **107**:19163–6 (2010).
- 501 56. Baret J-C, Miller OJ, Taly V, Ryckelynck M, El-Harrak A, Frenz L, Rick C, Samuels ML, Hutchison JB,
502 Agresti JJ, Link DR, Weitz DA, and Griffiths AD. Fluorescence-activated droplet sorting (FADS):
503 efficient microfluidic cell sorting based on enzymatic activity. *Lab Chip*. **9**:1850–8 (2009).
- 504 57. Sciambi A, and Abate AR. Accurate microfluidic sorting of droplets at 30 kHz. *Lab Chip*. (2014).
- 505 58. Cho S, Kang D-K, Sim S, Geier F, Kim J-Y, Niu X, Edel JB, Chang S-I, Wootton RCR, Elvira KS, and
506 deMello AJ. Droplet-Based Microfluidic Platform for High-Throughput, Multi-Parameter Screening of
507 Photosensitizer Activity. *Anal Chem*. **85**:8866–72 (2013).
- 508 59. Schoeman RM, Kemna EWM, Wolbers F, and van den Berg A. High-throughput deterministic single-cell
509 encapsulation and droplet pairing, fusion, and shrinkage in a single microfluidic device: Microfluidics and
510 Miniaturization. *ELECTROPHORESIS*. **35**:385–92 (2014).
- 511 60. Hudson SD. Wall migration and shear-induced diffusion of fluid droplets in emulsions. *Phys Fluids 1994-*
512 *Present*. **15**:1106–13 (2003).
- 513 61. Lagus TP, and Edd JF. High-throughput co-encapsulation of self-ordered cell trains: cell pair interactions
514 in microdroplets. *RSC Adv*. **3**:20512–22 (2013).
- 515 62. Kemna EWM, Schoeman RM, Wolbers F, Vermes I, Weitz DA, and van den Berg A. High-yield cell
516 ordering and deterministic cell-in-droplet encapsulation using Dean flow in a curved microchannel. *Lab*
517 *Chip*. **12**:2881 (2012).
- 518 63. Lee M, Collins JW, Aubrecht DM, Sperling RA, Solomon L, Ha J-W, Yi G-R, Weitz DA, and Manoharan
519 VN. Synchronized reinjection and coalescence of droplets in microfluidics. *Lab Chip*. **14**:509–13 (2013).
- 520 64. Huebner A, Srisa-Art M, Holt D, Abell C, Hollfelder F, deMello AJ, and Edel JB. Quantitative detection
521 of protein expression in single cells using droplet microfluidics. *Chem Commun*. 1218 (2007).
- 522 65. Mazutis L, Gilbert J, Ung WL, Weitz DA, Griffiths AD, and Heyman JA. Single-cell analysis and sorting
523 using droplet-based microfluidics. *Nat Protoc*. **8**:870–91 (2013).
- 524 66. Carlo DD. Inertial microfluidics. *Lab Chip*. **9**:3038–46 (2009).
- 525 67. Carlo DD, Irimia D, Tompkins RG, and Toner M. Continuous inertial focusing, ordering, and separation
526 of particles in microchannels. *Proc Natl Acad Sci*. **104**:18892–7 (2007).

- 527 68. Edd JF, Carlo DD, Humphry KJ, Köster S, Irimia D, Weitz DA, and Toner M. Controlled encapsulation
528 of single-cells into monodisperse picolitre drops. *Lab Chip*. **8**:1262–4 (2008).
- 529 69. Amini H, Lee W, and Carlo DD. Inertial microfluidic physics. *Lab Chip*. **14**:2739–61 (2014).
- 530 70. Chabert M, and Viovy J-L. Microfluidic high-throughput encapsulation and hydrodynamic self-sorting of
531 single cells. *Proc Natl Acad Sci*. **105**:3191–6 (2008).
- 532 71. Guillot P, Colin A, Utada AS, and Ajdari A. Stability of a Jet in Confined Pressure-Driven Biphasic
533 Flows at Low Reynolds Numbers. *Phys Rev Lett*. **99**:104502 (2007).
- 534 72. Chan PC-H, and Leal LG. The motion of a deformable drop in a second-order fluid. *J Fluid Mech*.
535 **92**:131–70 (1979).
- 536 73. Agresti JJ, Antipov E, Abate AR, Ahn K, Rowat AC, Baret J-C, Marquez M, Klibanov AM, Griffiths AD,
537 and Weitz DA. Ultrahigh-throughput screening in drop-based microfluidics for directed evolution. *Proc*
538 *Natl Acad Sci U S A*. **107**:4004–9 (2010).
- 539 74. Eisenstein M. Cell sorting: Divide and conquer. *Nature*. **441**:1179–85 (2006).
- 540 75. Frenz L, Blouwolff J, Griffiths AD, and Baret J-C. Microfluidic Production of Droplet Pairs. *Langmuir*.
541 **24**:12073–6 (2008).
- 542 76. Frenz L, Harrak A El, Pauly M, Bégin-Colin S, Griffiths AD, and Baret J-C. Droplet-Based Microreactors
543 for the Synthesis of Magnetic Iron Oxide Nanoparticles. *Angew Chem Int Ed*. **47**:6817–20 (2008).
- 544 77. Hong J, Choi M, Edel JB, and deMello AJ. Passive self-synchronized two-droplet generation. *Lab Chip*.
545 **10**:2702–9 (2010).
- 546 78. Chokkalingam V, Herminghaus S, and Seemann R. Self-synchronizing pairwise production of
547 monodisperse droplets by microfluidic step emulsification. *Appl Phys Lett*. **93**:254101 (2008).
- 548 79. Dangla R, Fradet E, Lopez Y, and Baroud CN. The physical mechanisms of step emulsification. *J Phys*
549 *Appl Phys*. **46**:114003 (2013).
- 550 80. Dressler O, Yang T, Chang S-I, Choo J, Wootton RCR, and deMello A. Continuous and low error-rate
551 passive synchronization of pre-formed droplets. *RSC Adv*. (2015).
- 552 81. Zagnoni M, and Cooper JM. On-chip electrocoalescence of microdroplets as a function of voltage,
553 frequency and droplet size. *Lab Chip*. **9**:2652–8 (2009).
- 554 82. Zagnoni M, Le Lain G, and Cooper JM. Electrocoalescence Mechanisms of Microdroplets Using
555 Localized Electric Fields in Microfluidic Channels. *Langmuir*. **26**:14443–9 (2010).
- 556 83. Akartuna I, Aubrecht DM, Kodger TE, and Weitz DA. Chemically induced coalescence in droplet-based
557 microfluidics. *Lab Chip*. **15**:1140–4 (2015).
- 558 84. Baroud CN, Vincent MR de S, and Delville J-P. An optical toolbox for total control of droplet
559 microfluidics. *Lab Chip*. **7**:1029–33 (2007).
- 560 85. Mazutis L, Baret J-C, and Griffiths AD. A fast and efficient microfluidic system for highly selective one-
561 to-one droplet fusion. *Lab Chip*. **9**:2665–72 (2009).
- 562 86. Liu K, Ding H, Chen Y, and Zhao X-Z. Droplet-based synthetic method using microflow focusing and
563 droplet fusion. *Microfluid Nanofluidics*. **3**:239–43 (2006).
- 564 87. Yoon DH, Jamshaid A, Ito J, Nakahara A, Tanaka D, Akitsu T, Sekiguchi T, and Shoji S. Active
565 microdroplet merging by hydrodynamic flow control using a pneumatic actuator-assisted pillar structure.
566 *Lab Chip*. **14**:3050–5 (2014).